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Abstract
The major goal in the treatment of diabetes mellitus is to achieve near-normal glycemic control. To optimize both fasting blood glucose and
postprandial glucose levels is important in keeping blood glucose levels as close to normal as possible. α -Glucosidase is the enzyme that digests 
dietary carbohydrate, and inhibition of this enzyme could suppress postprandial hyperglycemia. The purpose of this study was to test the inhibitory
activity of methanol extract of Euonymus alatus on α -glucosidase in vitro and in vivo to evaluate its possible use as an anti-diabetic agent. Yeast
α -glucosidase inhibitory activities of methanol extract of E. alatus were measured at concentrations of 0.50, 0.25, 0.10, and 0.05 mg/ml. The ability
of E. alatus to lower postprandial glucose was studied in streptozotocin-induced diabetic rats.  A starch solution (1 g/kg) with and without E. alatus
extract (500 mg/kg) was administered to diabetic rats by gastric intubation after an overnight fast. Plasma glucose levels were measured at 30, 60,
90, 120, 180, and 240 min. Plasma glucose levels were expressed in increments from baseline, and incremental areas under the response curve
were calculated. Extract of E. alatus, which had an IC50  value of 0.272 mg/ml, inhibited yeast α -glucosidase activity in a concentration-dependent 
manner.  A single oral dose of E. alatus extract significantly inhibited increases in blood glucose levels at 60 and 90 min (p＜0.05) and significantly
decreased incremental response areas under the glycemic response curve (p＜0.05).  These results suggest that E. alatus has an antihyperglycemic
effect by inhibiting α -glucosidase activity in this animal model of diabetes mellitus. 
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Introduction4)
Diabetes is the fifth leading cause of death among Koreans 
(Korea National Statistical Office, 2006). The prevalence of 
diabetes mellitus is increasing markedly because of an aging 
population, increased urbanization, and more sedentary lifestyles 
(King et al., 1998). Keeping blood glucose levels close to normal 
and preventing diabetic complications are the major goals in the 
treatment of diabetes mellitus (DCCT Research Group, 1993; 
UKPDS Group, 1998). Cardiovascular disease (CVD), a major 
complication of diabetes, is the major cause of morbidity and 
mortality in
  patients with diabetes (Centers for Disease Control 
and Prevention, 1999). Achieving near-normal glycemic control 
in patients with diabetes mellitus is associated with sustained 
and decreased rates of diabetes-related cardiovascular compli-
cations (DCCT Research Group, 1993; UKPDS Group, 
1998).  Optimizing both fasting blood glucose and postprandial 
glucose levels is important in achieving near-normal glucose 
levels (Abrahamson, 2004). Avignon et al. (1997) reported that 
postprandial glucose levels could be a better marker of glycemic 
control than fasting blood glucose levels in patients with type 
2 diabetes. Microvascular and macrovascular complications are 
strongly associated with postprandial hyperglycemia
  (Baron, 
1998; Haller, 1998; Jenkins et al., 1988; Mooradian & Thurman, 
1998).
At present, α -glucosidase inhibitors are the most common oral 
agents used to decrease postprandial hyperglycemia, since they 
can delay the digestion of dietary carbohydrates, resulting in 
retardation of glucose absorption (Saito et al., 1998; Sels et al., 
1999; Stand et al., 1999). In addition, numerous studies have 
been carried out to isolate effective and safe α -glucosidase 
inhibitors from natural products, including plant materials, as 
alternative hypoglycemic agents for diabetes that can be used 
in addition to conventional treatments (Joo et al., 2006; Li et 
al., 2005; Shim et al., 2003; Youn et al., 2004).
Euonymus alatus, known as ‘gui-jun woo’ in Korea, has been 
used in Asian folk medicine to treat tumors, regulate blood 
circulation, and relieve pain in countries including Korea and 
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China (Kim et al., 2006; Park et al., 2005). However, there is 
not enough scientific evidence to support the medical use of E. 
alatus. Euonymus alatus has anticancer (Lee et al., 1993) and 
antioxidative (Oh et al., 2005; Seo et al., 2003) properties and 
is effective in preventing hyperglycemia and hyperlipidemia in 
mice fed high-fat diets (Park et al., 2005). Activation of mRNA 
expression of PPARγ  by E. alatus extract could improve insulin 
resistance and hyperlipidemia and thus help to prevent obesity- 
related type 2 diabetes.
Controlling postprandial glucose levels is an also important 
strategy in the prevention of type 2 diabetes (Jermendy, 2005). 
Clinical studies have documented that α -glucosidase inhibitor is 
effective in controlling both fasting and postprandial hyper-
glycemia in patients with diabetes (Balflour & McTavish, 1993; 
Coniff et al., 1995; Holman et al., 1999), and the relative risk 
of type 2 diabetes could be decreased by α -glucosidase inhibitors 
in subjects with impaired glucose tolerance and obesity 
(Jermendy, 2005). Thus, in this study we measured the α
-glucosidase inhibitory activity of E. alatus in vitro and in vivo 
to evaluate its possible use as an anti-diabetic agent.
Materials and Methods 
Reagents 
Yeast α -glucosidase, p-nitropheny-α -D-glucopyranoside, solu-
ble starch, and streptozotocin (STZ) were purchased from Sigma 
Chemical Co (St. Louis, MO, USA). A glucose assay kit was 
obtained from Yeongdong Co (Seoul, South Korea). 
Preparation of the methanol extract 
Euonymus alatus was obtained from a local market in Busan, 
Korea. Leaves of Euonymus alatus was powdered and extracted 
with ten volumes of methanol for 12 h three times at room 
temperature. The solvent was removed by rotary evaporation at 
40℃. The extraction yield was 9.5%, and the extract was 
dissolved in dimethylsulfoxide (DMSO) at a concentration of 5 
mg/ml to be used as a test sample.
Measurement of yeast α -glucosidase inhibitory activity in vitro
Yeast α -glucosidase inhibitory activity was determined using 
the chromogenic method developed by Watanabe et al.
  (1997). 
Yeast  α -glucosidase (0.7 U) dissolved in 100 mM phosphate 
buffer (pH 7.0) containing 2 g/l bovine serum albumin, and 0.2 
g/l NaN3, and 5 mM p-nitrophenyl-α -D-glucopyranoside in the 
same buffer (pH 7.0) were used as an enzyme and a substrate 
solution, respectively.  The enzyme solution (50 μ l) and 10 μ l 
of the test sample at various concentrations were mixed, and 
absorbance at 405 nm was measured using a microplate reader 
(model 550, BioRad, Hercules, CA, USA). After incubation for 
5 min, 50 μ l of the substrate solution were added and incubated 
for an additional 5 min. The increase in absorbance from time 
zero was measured, and inhibitory activity was calculated as a 
percentage of the blank control. The inhibitory activities of the 
E. alatus extract and acarbose, a positive control, against α
-glucosidase were measured at concentrations of 0.50, 0.25, 0.10, 
and 0.05 mg/ml. The measurements were performed in triplicate, 
and the IC50 value, i.e., the concentration of the extract that results 
in 50% inhibition of maximal activity, was determined.
Animals 
Male Sprague-Dawley rats weighing between 250 and 280 g 
were purchased from Bio Genomics, Inc. (Seoul, Korea). The rats 
were housed individually in stainless steel wire-bottomed cages 
and located in a room where temperature (23-27℃), humidity 
(50-60%), and light (0600-1800 hr light and 1800-0600 hr dark 
cycle) were controlled. The animals were fed a commercial chow 
(Samyang Co., Seoul, Korea) ad libitum for 14 d after 
arrival. They were rendered diabetic by intravenous injection of 
STZ (60 mg/kg) in citrate buffer, pH 4.5. Blood samples were 
taken from the tail tip after 7 d, and blood glucose concentration 
was measured using a glucometer (Glucotrend Roche 
Diagnostics, United Kingdom).  Animals showing fasting blood 
glucose levels higher than 200 mg/dl were considered diabetic 
and used for further study.  All animals continued to be fed 
commercial chow.
Measurement of postprandial blood glucose 
The effect of E. alatus extract on postprandial glucose was 
measured in STZ-induced diabetic rats (n=16).  The rats were 
randomly divided into two groups. After an overnight fast, fasting 
blood samples were collected from the tail tip.  The rats were 
given soluble starch (1 g/kg) alone or starch with methanol 
extract of E. alatus (500 mg/kg) by gastric intubation.  Blood 
samples were collected from the tail tip at 30, 60, 90, 120, 180, 
and 240 min. Food was withheld during the test. Blood samples 
were centrifuged at 3,000 rpm for 15 min. Plasma glucose was 
measured using a commercial glucose oxidase kit (Yeongdong 
Co., Seoul, Korea). The plasma glucose level was expressed in 
increments from the baseline.  Incremental areas under the 
response curve (AUC) were calculated using the trapezoidal rule 
with fasting levels as the baseline. All experiments were per-
formed according to the guidelines of animal experimentation 
approved by the Animal Resource Center at Inje University.
Statistical analysis 
Increment plasma glucose level and AUC of the glucose 
response curve were expressed as mean ± standard error (SE). All 
statistical analyses were performed using SAS (version 8.02). 
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Fig. 1. Dose-dependent inhibition of yeast α -glucosidase activity of Euonymus 
alatus and acarbose. The inhibitory activities of the methanol extract of Euonymus 
alatus or acarbose were measured at concentrations of 0.5, 0.25, 0.1, and 0.05 
mg/ml.  ,  Euonymus  alatus  extract;  ◆,  acarbose.  Values  represent  means  of 
triplicate  measurements.
Table 1. Area under the curve (AUC) of postprandial glucose responses 
of  STZ-induced diabetic  rats
 Group AUC (mg․min/dl)
Control group  12,541 ± 951
Euonymus alatus group 9,350 ± 668*
Control group: Starch (1 g/kg) was administered orally to a rat after an overnight- 
fast. Euonymus alatus group: starch (1 g/kg) with the methanol extract of Euony-
mus alatus (500 mg/kg) was administered orally to a rat after an overnight-fast. 
Values  represent  mean ± SE  (n=8). 
*Significantly  different  at  p＜0.05.
Fig. 2. Postprandial glucose response to Euonymus alatus extract in 
STZ-induced diabetic rats. I n  t h e  c o n t r o l  g r o u p  ( ) ,  s t a r c h  ( 1  g / k g )  w a s  
administered orally to rats after an overnight fast. In the  Euonymus alatus group 
(◆),  starch  (1  g/kg)  plus  Euonymus  alatus  methanol  extract  (500  mg/kg)  was 
administered orally to rats after an overnight fast. Values represent mean ± SE (n
=8 ) .  *S i g n i f i c a n t l y  d i f f e r e n t  a t  p ＜0.05.
between the control group and the Euonymus alatus group were 
assessed using Student's t-test. Significance was defined as 
p＜0.05. 
Results
Inhibition of α -glucosidase activity in vitro 
The inhibitory activity of the methanol extract of E. alatus 
against yeast α -glucosidase is shown in Fig. 1.  The methanol 
extract of E. alatus inhibited yeast α -glucosidase activity by 69.4, 
48.1, 24.5, 11.3, and 4.2% at concentrations of 0.50, 0.25, 0.10, 
0.05, and 0.025 mg/ml in vitro, respectively. Acarbose, an α
-glucosidase inhibitor used as an oral hypoglycemic agent, 
inhibited enzyme activity by 26.5, 20.1, 11.4, and 4.5% at 
concentrations of 0.50, 0.25, 0.10, and 0.05 mg/ml, respectively. 
The  E. alatus extract had an IC50  value of 0.272 mg/ml. 
Inhibition of α -glucosidase activity in vivo 
The plasma glucose response to a single oral dose of starch 
(1 g/kg) alone or starch with E. alatus extract (500 mg/kg) is 
shown in Fig. 2. The incremental plasma glucose levels of the 
rats that consumed starch were 53.8 ± 8.5, 91.5 ± 5.5, 115.3 ± 
10.3, 80.3 ± 8.6, 36.1 ± 5.2, and -0.8 ± 3.2 mg/dl at 30, 60, 90, 
120, 180, and 240 min, respectively.  The incremental plasma 
glucose levels of the rats that consumed E. alatus extract with 
starch were 39.4 ± 10.0, 70.8 ± 5.6, 87.8 ± 7.4, 64.8 ± 5.6, 23.1
± 4.2, -4.6 ± 3.8 mg/dl at 30, 60, 90, 120, 180, and 240 min, 
respectively. Consumption of E. alatus extract significantly de-
creased incremental plasma glucose levels at 60 and 90 min (p
＜0.05). The AUC for the glucose response of the E. alatus group 
(9,350 ± 668 mg·min/dl) was significantly lower than that of the 
control group (12,541 ± 951 mg·min/dl, p＜0.05, Table 1). 
Discussion
α -Glucosidase is a key enzyme in carbohydrate digestion in 
the small intestine (Li et al., 2005).
  Therefore,  α -glucosidase 
inhibitors could delay digestion of dietary carbohydrates to 
reduce postprandial glucose.  In fact, α -glucosidase inhibitors 
have become the most common oral agents used to improve 
postprandial hyperglycemia since their introduction in the early 
1990s (Mooradian & Thurman, 1999). However, because the 
chronic use of synthetic α -glucosidase inhibitors can have 
undesirable side effects, such as flatulence, diarrhea, and 
abdominal cramping, their use may be limited (Mooradian & 
Thurman, 1999).  Therefore, attention has focused on natural 
substances that show potent inhibitory activity against α
-glucosidase and have fewer side effects (Joo et al., 2006; Li 
et al., 2005; Shim et al., 2003; Youn et al., 2004). Galls of Rhus 
chinensis (Shim et al., 2003), Commelina communis L. (Youn 
et al., 2004), flowers of Punica granatum (Li et al., 2005), and 
Saururus chinensis Baill (Joo et al., 2006) have shown potent 
inhibitory activity against α -glucosidase. 
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against α -glucosidase to elucidate the possible use of E. alatus 
as an antihyperglycemic agent. Inhibition activity of the methanol 
extract of E. alatus against yeast α -glucosidase was about 2.6 
times that of acarbose in vitro at a concentration of 0.5 mg/ml 
(Fig. 1).  Euonymus alatus extract showed inhibitory activity 
against yeast α -glucosidase in a dose-dependent manner and had 
an IC50  value of 0.272 mg/ml.
We determined the effect of E. alatus on postprandial hyper-
glycemia in STZ-induced diabetic rats after consumption of 
starch.  Postprandial plasma glucose peaked 90 min after con-
sumption of starch in the control group.  The E. alatus extract 
significantly suppressed incremental plasma glucose at 60 and 
90 min (Fig. 2) and significantly decreased the AUC for the 
glucose response curve.  These data demonstrate that E. alatus 
exerts  α -glucosidase inhibitory activity in vivo to decrease 
postprandial glucose levels. Inoue et al. (1997) reported that an 
α -glucosidase inhibitor that flattens the peak postprandial blood 
glucose levels reduces the AUC of the blood glucose response 
curve. In our study, E. alatus extract decreased both incremental 
blood glucose at the peak time point and the AUC. 
Postprandial hyperglycemia is one of the earliest observable 
abnormalities in diabetes mellitus. Postprandial hyperglycemia is 
highly correlated with glycated hemoglobin levels and is a better 
predictor of glycated hemoglobin levels than fasting glucose 
(Soonthornpun  et al., 1999).  Glycated hemoglobin is highly 
associated with a higher risk of cardiovascular disease and 
coronary heart disease mortality (Campbell et al., 2001). 
Postprandial hyperglycemia is strongly correlated with risks for 
micro- and macrovascular complications of diabetes (Campbell 
et al., 2001). Bastyr et al.
  (2000) demonstrated that diabetes 
therapy focused on lowering postprandial glucose rather than 
fasting glucose could be a better treatment. 
In conclusion, E. alatus showed strong inhibitory activity 
against  α -glucosidase in vitro and in vivo. Thus, chronic 
consumption of E. alatus could be helpful in improving 
hyperglycemia and preventing diabetic complications. Further 
study to identify the active component responsible for the 
inhibition of α -glucosidase is strongly recommended.
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